A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Brief summary (registry, in English)

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.

What you commit to

• Study type: Interventional · Phase 3
• Participants enrolled: 822
• From 8 Nov 2022 to the primary completion date, 30 Oct 2026
• 193 sites in 23 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (193)

Sites in registry order. Save your city in your profile to sort them by distance.